Email updates

Keep up to date with the latest news and content from BMC Clinical Pathology and BioMed Central.

Open Access Research article

Clinical chemistry profiles in injection heroin users from Coastal Region, Kenya

Tom Were1*, Jesca O Wesongah2, Elly Munde3, Collins Ouma3, Titus M Kahiga4, Francisca Ongecha-Owuor5, James N Kiarie6, Aabid A Ahmed7, Ernest P Makokha8 and Valentine Budambula9

Author Affiliations

1 Department of Clinical Medicine, University of Kabianga, P. O. Box 2030–20200, Kericho, Kenya

2 Department of Medical Laboratory Sciences, Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya

3 Department of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya

4 Department of Pharmacy and Complementary Medicine, Kenyatta University, Nairobi, Kenya

5 Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya

6 Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya

7 Bomu Hospital, Mombasa, Kenya

8 Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya

9 Department of Environment and Health Sciences, Technical University of Mombasa, Mombasa, Kenya

For all author emails, please log on.

BMC Clinical Pathology 2014, 14:32  doi:10.1186/1472-6890-14-32

Published: 9 July 2014

Abstract

Background

Although the co-burden of injection drug use and HIV is increasing in Africa, little is known about the laboratory markers of injection drug use and anti-retroviral treatment (ART) in Kenyan injection drug users. This study, therefore, aimed at determining the clinical chemistry profiles and identifying the key laboratory markers of HIV infection during ART in injection heroin users (IHUs).

Methods

Clinical chemistry measurements were performed on serum samples collected from HIV-1 infected ART-experienced (n = 22), naive (n = 16) and HIV-1 negative (n = 23) IHUs, and healthy controls (n = 15) from Mombasa, coastal Kenya.

Results

HIV uninfected IHUs had lower alanine aminotransferase (ALT) levels (P = 0.023) as ART-exposed IHUs exhibited lower albumin (P = 0.014) and higher AST to platelet index (APRI) (P < 0.0001). All IHUs presented with lower aspartate aminotransferase to ALT values (P = 0.001) and higher C-reactive protein (CRP) levels (P = 0.002). ART-naive IHUs had higher globulin levels (P = 0.013) while ART-experienced and naive IHUs had higher albumin to total protein (P < 0.0001) and albumin to globulin (P < 0.0001) values. In addition, CD4+ T cells correlated with ALT (ρ = −0.522, P = 0.011) and CRP (rho, ρ = 0.529, P = 0.011) in HIV negative and ART-experienced IHUs, respectively. HIV-1 viral load correlated with albumin to globulin index in ART-experienced (ρ = −0.468, P = 0.037) and naive (ρ = −0.554, P = 0.040) IHUs; and with albumin to total protein index (ρ = −0.554, P = 0.040) and globulin (ρ = 0.570, P = 0.033) in ART-naive IHUs.

Conclusion

Absolute ALT, albumin, globulin, and CRP measurements in combination with APRI, AST to ALT, albumin to total protein and albumin to globulin indices may be useful laboratory markers for screening IHUs for initiating and monitoring treatment.

Keywords:
Injection heroin user; Clinical chemistry markers; HIV-1 infection; Anti-retroviral treatment